Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Fuji
Colorcon
Cerilliant
Citi
Baxter
Boehringer Ingelheim
Queensland Health
Moodys

Generated: May 23, 2018

DrugPatentWatch Database Preview

OPTIRAY 240 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Optiray 240 patents expire, and what generic alternatives are available?

Optiray 240 is a drug marketed by Liebel-flarsheim and is included in two NDAs.

The generic ingredient in OPTIRAY 240 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
Drug patent expirations by year for OPTIRAY 240
Pharmacology for OPTIRAY 240
Synonyms for OPTIRAY 240
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-
771I402
8771-40-2
87771-40-2
AB00513943
AB00513943_02
AC-536
AC1L1GLW
AC1Q4PBO
AKOS015896385
AMDBBAQNWSUWGN-UHFFFAOYSA-N
AN-15742
API0003020
AS-12851
BC215938
BPBio1_001051
BRD-A65818372-001-01-2
BRN 7155654
BSPBio_000955
C18H24I3N3O9
CAS-87771-40-2
CCG-213209
CHEBI:31717
CHEBI:94420
CHEMBL1200614
CS-7483
CTK3E8473
D01555
D0U1ZD
DB09134
DR003574
DSSTox_CID_25521
DSSTox_GSID_45521
DSSTox_RID_80927
DTXSID2045521
FT-0627284
HMS1570P17
HMS2097P17
HY-B1410
I06-1983
ioversol
Ioversol (JAN/USP/INN)
Ioversol [USAN:INN:BAN]
Ioversol [USAN:USP:INN:BAN]
Ioversolum
Ioversolum [Latin]
joversol
LOVERSOL
LS-29726
MolPort-005-938-391
MP 328
MP-328
N,N'-Bis (2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamide
N,N'-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2-1,3-benzenedicarboxamide
n,n'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(2-hydroxyethyl)amino]-2,4,6-triiodoisophthalamide
N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodo-benzene-1,3-dicarboxamide
N1,N3-bis(2,3-dihydroxypropyl)-5-[2-hydroxyethyl-(2-hydroxy-1-oxoethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
N3RIB7X24K
NCGC00016956-01
NCGC00179364-01
NCGC00179364-03
NSC-760064
NSC760064
Optiray
Optiray (TN)
Optiray 160
Optiray 300
Optiray 320
Optiray 350
OR214205
OR356357
P 530
Pharmakon1600-01503837
Prestwick0_000878
Prestwick1_000878
Prestwick2_000878
Prestwick3_000878
Q-201247
SCHEMBL24711
SPBio_002876
SR-01000872680
SR-01000872680-1
Tox21_110709
Tox21_110709_1
UNII-N3RIB7X24K

US Patents and Regulatory Information for OPTIRAY 240

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 019710-002 Dec 30, 1988 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for OPTIRAY 240

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 019710-002 Dec 30, 1988 ➤ Try a Free Trial ➤ Try a Free Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Daiichi Sankyo
Julphar
Cantor Fitzgerald
US Department of Justice
Harvard Business School
Boehringer Ingelheim
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.